<DOC>
	<DOCNO>NCT02338609</DOCNO>
	<brief_summary>The primary objective CRAD001M2305 report long-term effect everolimus treatment height , weight sexual development ( use Tanner Stages ) child adolescents Tuberous Sclerosis Complex ( TSC ) -associated Subependymal Giant Cell Astrocytoma ( SEGA ) . The study monitor growth development pediatric patient TSC-associated SEGA , previously enrol CRAD001M2301 reach Tanner Stage V , age 16 female 17 male whichever occur first .</brief_summary>
	<brief_title>Long-term Follow-up Growth Development Pediatric Patients From CRAD001M2301</brief_title>
	<detailed_description>CRAD001M2305 prospective , multi-center phase IIIb/IV study . This study investigate physical sexual development pediatric patient affect previous ongoing treatment everolimus . The study monitor growth development pediatric patient TSC-associated SEGA , previously enrol CRAD001M2301 reach Tanner Stage V , age 16 female 17 male whichever occur first . Continued treatment everolimus investigator discretion require participation CRAD001M2305 . Growth ( height , weight ) , sexual development ( Tanner Stages , sex hormone level , age menarche , thelarche ( female ) adrenarche ( male ) ) , brain development ( assessed TAND Checklist , date brain MRI ) patient participate long-term follow-up study follow annual visit site patient achieve Tanner Stage V age 16 ( female ) , age 17 ( male ) whichever occur first . Adverse event , concomitant medication , appearance menarche , monitor data collect every 3 month ( `` 3-monthly '' ) . Unless clinically indicate 3-monthly visit perform per telephone .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Pediatric female patient study treatment study [ CRAD001M2301 ] within past 63 month reach Tanner Stage V age 16 time completion [ CRAD001M2301 ] Pediatric male patient study treatment study [ CRAD001M2301 ] within past 6 month reach Tanner Stage V age 17 time completion [ CRAD001M2301 ] Written inform consent accord local guideline Pediatric female patient study treatment CRAD001M2301 reach Tanner Stage V within 3 month turn age 16 Pediatric male patient study treatment CRAD001M2301 reach Tanner Stage V within 3 month turn age 17 Any patient pregnant prior start CRAD001M2305 Other protocoldefined Inclusion/Exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>TSC-associated SEGA ,</keyword>
	<keyword>height ,</keyword>
	<keyword>weight ,</keyword>
	<keyword>Tanner Stage ,</keyword>
	<keyword>growth development ,</keyword>
	<keyword>everolimus ,</keyword>
	<keyword>RAD001</keyword>
</DOC>